<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04966962</url>
  </required_header>
  <id_info>
    <org_study_id>SysMU-diag1</org_study_id>
    <nct_id>NCT04966962</nct_id>
  </id_info>
  <brief_title>Establishment and Validation of an Early Diagnostic Model for Bladder Cancer Based on Serum and Urine Metabolomics</brief_title>
  <official_title>Establishment and Validation of an Early Diagnostic Model for Bladder Cancer Based on Serum and Urine Metabolomics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Third Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Seventh Affiliated Hospital of Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolomics is a complementary approach for identifying perturbed metabolic pathways. The&#xD;
      goal of this study is to establish and validate an early diagnostic model for bladder cancer&#xD;
      by metabolomics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Early diagnosis and life-long surveillance are clinically important to improve the long-term&#xD;
      survival of bladder cancer patients. Currently, a noninvasive biomarker that is as sensitive&#xD;
      and specific as cystoscopy in detecting bladder cancer is lacking. Metabolomics are small&#xD;
      organic molecules (below 2000 mass units) that are products of complex pathways. This is a&#xD;
      prospective study aims to create an early diagnostic model based on serum and urine&#xD;
      metabolomics. Commonly employed metabolomics analytical platforms include nuclear magnetic&#xD;
      resonance spectroscopy (NMR), gas chromatography mass spectrometry (GC-MS), and liquid&#xD;
      chromatography mass spectrometry （LC-MS）. The diagnostic model will be made to distinguish&#xD;
      bladder cancer and benign disease of the urinary system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement the sensitivity of diagnostic model based on urine and serum metabolomics in differentiating between bladder cancer and benign disease of the urinary system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement the specificity of diagnostic model based on urine and serum metabolomics in differentiating between bladder cancer and benign disease of the urinary system</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Bladder cancer</arm_group_label>
    <description>Patients who diagnosis with incident or recurrent bladder cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>benign disease of urinary system</arm_group_label>
    <description>Patients who clinically diagnosis with benign disease of the urinary system, such as urinary calculi and benign prostatic hyperplasia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum and urine metabolomics</intervention_name>
    <description>serum and urine samples will be collected for metabolomics analysis</description>
    <arm_group_label>Bladder cancer</arm_group_label>
    <arm_group_label>benign disease of urinary system</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with bladder cancer or benign. disease of urinary system will be&#xD;
        enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Bladder cancer group:&#xD;
&#xD;
          1. Any male or female patient aged 18 or older&#xD;
&#xD;
          2. Able to provide serum and urine specimen before treatment&#xD;
&#xD;
          3. Diagnosis with incident or recurrent bladder cancer&#xD;
&#xD;
        Control group&#xD;
&#xD;
          1. Any male or female patient aged 18 or older&#xD;
&#xD;
          2. Able to provide serum and urine specimen before treatment&#xD;
&#xD;
          3. Diagnosis with benign disease of the urinary system, such as urinary calculi and&#xD;
             benign prostatic hyperplasia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Kidney and liver dysfunction.&#xD;
&#xD;
          2. Incomplete clinical information and laboratory test result&#xD;
&#xD;
          3. Tumor-related treatment was received preoperatively&#xD;
&#xD;
          4. Preoperative routine examination and medical history indicate a history of diabetes,&#xD;
             hyperlipidemia and other metabolic diseases or other malignant tumors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jian Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen Memorial Hospital,Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hao Chen</last_name>
    <phone>+86-02034078960</phone>
    <email>chenh585@mail2.sysu.edu.cn</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>July 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>July 15, 2021</last_update_submitted>
  <last_update_submitted_qc>July 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bladder cancer</keyword>
  <keyword>metabolomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

